On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

Novo Nordisk saw a slight rise in shares after withdrawing its bid for U.S. weight loss drug company Metsera, losing out to Pfizer in a bidding war. Pfizer secured a $10 billion deal, marking a ...

The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...

Competition is working, even as the FTC meddles in a takeover fight in a way that helped Pfizer.

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...